REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Cyclopentanohydrophenanthrene Ring System Doai > Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring SystemOxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010505 - Methods of treating disease states using antiangiogenic agents wherein the variables are defined in the specification. ... 01/04/07 - 20070004694 - Estrogen compositions for vaginal administration Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed. ... 01/04/07 - 20070004693 - Estrogen compositions for vaginal administration Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed. ... 11/02/06 - 20060247221 - Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy in which formula R1, R2, R3, R4, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances ... 10/26/06 - 20060241094 - Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use Disclosed are compositions for treating an estrogen receptor (ER) or estrogen related receptor (ERR) mediated disorder, comprising a therapeutically effective amount of a compound selected from the group consisting of Compound Nos. 1-9, 7-2, 7-4, 7-5, 7-7, 7-8, 8-2 and 3-15 set forth herein or a pharmaceutically acceptable salt thereof, ... 10/19/06 - 20060234994 - Method and device for concentrating and stabilizing conjugated estrogens from mare urine A method and apparatus for concentrating and stabilizing conjugated estrogens from pregnant mare urine on solid adsorbent supports to obtain a starting material for pharmaceuticals that contain a natural mixture of conjugated estrogen mixtures on cartridges in the vicinity of the horses. The adsorbent cartridges can be loaded at the ... 09/21/06 - 20060211673 - Modulation of neurodegenerative diseases through the estrogen receptor Methods for modulating hormonal pathways involving the estrogen receptor in a subject with a neurodegenerative disorder, are provided. Estrogen receptor activity is modulated by administering an effective amount of an estrogen receptor modulating pharmacological agent to a subject such that the estrogen receptor modulating pharmacological agent interacts with the estrogen ... 09/21/06 - 20060211672 - Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis The present invention provides a method of treating or inhibiting mucositis or radiation cystitis using an ERβ selective ligand. The present invention also provides compositions, including pharmaceutical compositions, containing the ERβ selective ligand and a traditional medicament for mucositis or radiation cystitis. ... 09/21/06 - 20060211671 - Estrogen receptors This invention relates to the field of estrogen receptors and particularly though not exclusively on the effect of estrogen receptors and ligands for estrogen receptors on the prevention or treatment of obesity. The invention also relates to the effect of estrogen receptors and their ligands on lipoprotein levels in mammals. ... 09/21/06 - 20060211670 - Antitumoral18a-homoestra-1,3,5(10)-trien-3yl 2-substituted sulfamates The invention relates to the use of compounds of a general formula (I), wherein R2, R14 to R17 and X groups have the following significance: R2 is C1-C5-Alkyl, C1-C5-Alkoxy or a —O—C<SB>N</SB>FmHo rest, wherein n=1,2,3,4,5 or 6, m>1 and m+o=2n+1, R14 and R15 separately designate hydrogen or together a methyl ... 09/21/06 - 20060211669 - Synthesis of estetrol via estrone derived steroids A process is provided for the making of estetrol starting from a 3-A-oxy-estra 1,3,5(10),15-tetraen-17-one, wherein A is a C1-C5 alkyl group, preferably a methyl group, or a C7-C12 benzylic group, preferably a benzyl group. This process is particularly suitable to industry. ... 08/31/06 - 20060194775 - Estradiol metabolites for the treatment of pulmonary hypertension Methods are provided for the treatment of pulmonary hypertension and other conditions associated therewith. In particular, the methods include treatment of pulmonary hypertension with an estradiol metabolite or alkoxy analogue of an estradiol metabolite. The estradiol metabolite or alkoxy analogue thereof may be associated with biodegradable microparticles or nanoparticles alone ... 08/17/06 - 20060183727 - Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods. ... 07/20/06 - 20060160782 - 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament Said compounds have an anti-tumour action. ... 06/29/06 - 20060142258 - Estrogen replacement therapy This invention relates to methods and pharmaceutical compositions for providing estrogen replacement therapy in penmenopausal, menopausal, and postmenopausal women through the continuous administration of conjugated estrogens. ... 06/01/06 - 20060116360 - Method of administering anti-angiogenic agents and a method of treating disease using same A method of administering an anti-angiogenic agent to a human or an animal comprising administering the anti-angiogenic agent such that a plasma concentration of the anti-angiogenic agent in the human or animal is substantially continuously maintained above 1 ng/mL. ... 05/25/06 - 20060111334 - Oral solid dosage forms containing a low dose of estradiol The present invention relates to oral solid dosage forms containing a very low dose of estradiol. The dosage forms are formulated in a manner so as to avoid degradation of the estradiol and to minimise the content of polyvinylpyrrolidone, while still achieving similar fast dissolution of the estradiol. The dosage ... 05/25/06 - 20060111333 - Structural, behavioral characterization, and synthesis of attractants for migratory lamprey Compounds that function as lamprey attractants and methods. ... 05/25/06 - 20060111332 - Process and intermediates to prepare17beta-hydroxy-7alpha-methyl-19-nor-17alpha-pregn -5(10)-en-20-yn-3-one The present invention is a process for the preparation of 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one (17α-ethynyl-17β-hydroxy-7α-methyl-5(10)-estren-3-one, tibolone) of formula 1, which comprises hydrolysis of 17α-ethynyl-17β-hydroxy-7α-methyl-5(10)-estrene 3,3-cyclic ketals of formula 2, where groups R1, R2, R3 and R4 are hydrogen atoms or alkyl groups, or R1 and R3, taken together with the carbon atoms within ... 04/20/06 - 20060084638 - Appetite-suppressing compositions and methods The invention relates to appetite-suppressing compositions obtained from botanical sources. More specifically, the invention relates to appetite-suppressing compositions comprising an extract product of an Asclepias plant, methods of making an appetite-suppressing composition, and methods of suppressing an appetite. ... 04/20/06 - 20060084637 - Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a thermogenic compound. Furthermore ... 02/23/06 - 20060040904 - Vaginal cream compositions, kits thereof and methods of using thereof The present invention is directed to pharmaceutical vaginal cream compositions comprising a conjugated estrogen and a stabilizer. The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated ... 02/09/06 - 20060030552 - Process for the preparation of 7alpha-alkylated 19-norsteroids Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant. ... 02/02/06 - 20060025394 - Estradiol-related compounds and methods of use as anti-tumor agents This invention relates to new estradiol-related compounds that can be used to treat various types of cancer including prostate and breast cancers. ... 02/02/06 - 20060025393 - Steroid derivatives This invention relates to methods for treating cancers. ... 01/26/06 - 20060019938 - Estrogen administration for treating male cognitive dysfunction or improving male cognitive function Disclosed are methods of treating a male subject diagnosed with cognitive dysfunction that include administering an estrogenic agent, or a pharmaceutically acceptable salt or complex thereof, to the male subject. Also disclosed is a method of improving cognitive function in a hypogonadal male subject that includes transdermally administering to the ... 01/19/06 - 20060014729 - Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production The present invention provides novel dammarane compounds, compositions (e.g., pharmaceutical compositions) comprising the dammarane compounds, and methods for the synthesis of these dammarane compounds. Additionally, the present invention provides methods for inhibiting beta-amyloid peptide production and methods for treating or preventing a pathological condition, particularly, neurodegeneration diseases (e.g., Alzheimer's disease), ... 01/12/06 - 20060009438 - Modified, hydroxy-substituted aromatic structures having cytoprotective activity The present invention is directed to a process for conferring cytoprotection on a population of cells which comprises administering to that population of cells a compound comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto. In particular, the present invention is directed to such ... 12/29/05 - 20050288268 - Preparation of 6-hydroxyequilenins This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents. ... 12/29/05 - 20050288267 - Estradiol prodrugs process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action. ... 12/22/05 - 20050282793 - Steroid prodrugs with androgenic action pharmaceutical compositions that contain these compounds as well as their use for the production of pharmaceutical agents with androgenic action. ... 12/15/05 - 20050277625 - Estriol and estetrol prodrugs process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action. ... 12/01/05 - 20050267086 - Compounds and methods for cytoprotection including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. ... 11/10/05 - 20050250751 - Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents along with methods of using such compounds for the treatment of cancer and pharmeutical formulations thereof. ... 11/10/05 - 20050250750 - Methods for treating postmenopausal women using ultra-low doses of estrogen The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present ... 10/27/05 - 20050239762 - Estriol therapy for multiple sclerosis and other autoimmune diseases The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 ... 10/20/05 - 20050234028 - Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17β-estradiol and a contraceptive method by oral administration ... 10/06/05 - 20050222115 - Bile acid derived steroidal dimers with novel amphiphilic topology having antifungal activity The need for new class of antifungal drugs with high efficacy, low toxicity and novel mode of action is well established. Synthesis and antifungal activity of bile acid derived new steroidal dimers N1,N3-Diethylenetriamine bis [cholic acid amide] (1) and N1,N3-Diethylenetriamine bis [deoxycholic acid amide] (2) having novel amphiphile topology is ... 10/06/05 - 20050222114 - Use of new etonogestrel esters The subject invention provides a contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of a long-acting etonogestrel ester with a fatty-chain length of C7-C15. ... 10/06/05 - 20050222113 - New etonogestrel esters The subject invention provides new progestogen esters and uses thereof. ... 09/29/05 - 20050215538 - Method of treating human skin and a skin care composition for use in such a method in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance ... 09/22/05 - 20050209209 - Hormone composition Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect. ... 09/22/05 - 20050209208 - Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders Methods, compositions and kits for treating psoriasis and other autoimmune diseases in human or animal subjects. The disclosed methods generally comprise administering to the subject a therapeutically effective amount of a naturally occurring or synthetic agent comprising estriol or another estrane, estrogen or estrogen receptor-effective composition. The disclosed compositions and ... 09/22/05 - 20050209207 - Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery The invention discloses formulations for administration with pressurized metered dose inhalers containing as active ingredient esters of 3,17-dihydroxy oestratriene derivatives, in solution in a hydrofluorocarbon propellant, optionally one or more co-solvents, and their use for the treatment of postmenopausal symptoms as well as of menstrual migraine headaches. ... 09/15/05 - 20050203075 - Antiangiogenic agents wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons. ... 08/04/05 - 20050171075 - Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy Formula (I) in which: R1 and R2, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R3 represents a methyl group having α- or β-configuration; R4 represents a hydrogen atom or an etherifying or esterifying group; R5 represents a hydrogen atom, a hydroxyl ... 07/28/05 - 20050164998 - Steroid extraction process from urine sources A process in which urine is optionally filtered to remove solid extraneous matter and optionally treated so as to reduce the phenolic content of the urine to give and the resulting fluid is then subjected to a solid extraction of the major concentration steroids content therefrom by a first suitable ... 07/21/05 - 20050159399 - Di-steroidal prodrugs of estradiol The present invention is a di-steroidal prodrug of estradiol having the following formula: ... 06/30/05 - 20050143366 - Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the acceleration of bone healing. ... ### FreshPatents.com Support |